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Crying Fire in a Theater” or
“Confirmatory Sighting?”*
tephen G. Ellis, MD, FACC
leveland, Ohio
ow should the cardiology community respond when
nformed of an apparent considerable increase in mortality
rom a procedure when data are derived from the only
andomized trial assessing the question, but that trial is
mall, the analysis post-hoc, and the result somewhat
ounterintuitive? That is the question raised by the report by
ermeersch et al. (1) in this issue of the Journal in
escribing an excess risk of late death after sirolimus-eluting
tent (SES) placement in patients with diseased saphenous
ein grafts (SVG), a group comprising 5% to 8% of all
atients undergoing percutaneous coronary intervention.
he importance of the question is magnified considering
he fact that we are speaking of drug-eluting stents (DES),
evices implanted in nearly 2 million patients annually
orldwide and for which other major safety questions have
risen recently (2–4).
See page 261
The SES and paclitaxel-eluting stents were approved for
se in Europe and the U.S. on the basis of short-term results
n highly selected patients, whose characteristics apply only
o approximately 40% of patients undergoing stenting
orldwide. Important subgroups of patients were excluded,
ncluding those with acute myocardial infarction, need for
ultivessel or complex stenting, those with restenosis and,
ermane to this discussion, those needing treatment of
iseased SVG.
Four-year outcomes in the well-studied “on-label” types
f patients generally have been reassuring, with carefully
onsidered meta-analyses showing a modest excess risk of
ate stent thrombosis offset by a reduction in restenosis-
elated adverse events and an overall neutral effect on the
nd point of death and myocardial infarction. Need for late
evascularization was markedly diminished (5).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.o
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or Cordis (Johnson & Johnson), Boston Scientific, and Abbott Vascular.Unanswered concern, however, has arisen regarding long-
erm adverse outcomes for the “off-label” group (2–4).
athophysiologic underpinnings of these clinical outcomes
ave been suggested to involve delayed reendothelialization
f the coronary artery after DES placement leading to stent
hrombosis (6), sirolimus activation of tissue factor (7)
likely a greater propensity for this in SVG? [8]), and
erhaps diminished capacity to develop collateral vessels in
he event of reblockage (9).
Into this mix are placed the results of the RRISC
Reduction of Restenosis In Saphenous vein grafts with
ypher sirolimus-eluting stent) study (1). Attempting to
ircumvent the inevitable biases confounding interpretation
f nonrandomized studies, the investigators commendably
ttempted to scientifically address the question as to
hether or not the Cypher SES (Cordis, Johnson &
ohnson, Miami Lakes, Florida) reduces angiographic re-
tenosis (late lumen loss) 6 months after stenting, in
omparison with bare-metal stenting, in patients with de
ovo SVG lesions (10). The patient population was notable
or well-preserved left ventricular function and the absence
f recent myocardial infarction, among other things. Non-
ardiac exclusions were limited to creatinine 3.0 mg/dl.
nly 75 patients were required to achieve 80% power for
he primary end point. Prespecified secondary end points
ere somewhat numerous, but none, either in the report or
linicaltrials.gov submission, extended beyond 6 months.
ate loss and target lesion/vessel revascularization were all
ignificantly reduced with the SES, and no adverse safety
ignal was noted (10).
Prompted by the aforementioned recent safety concerns
2–4), the authors obtained permission to evaluate these
atients for a longer period of time. Over an average two
nd a half year follow-up, 11 of 38 SES patients died,
ompared with 0 of 37 in the bare-metal stent group (p 
.001) (1). One death was directly due to stent thrombosis
hen the patient was off antiplatelet therapy for surgery, 3
ere out-of-hospital sudden deaths while taking at least one
ntiplatelet agent, and another occurred after redo bypass
urgery for restenosis and progressive disease elsewhere. Of
he patients with sudden cardiac death, ejection fractions
ere 70%, 32%, and 75%, suggesting that, at least for 2
atients, scar-related arrhythmia was an unlikely cause
thereby increasing the likelihood of a stent thrombosis-
ediated event). Other deaths could not be directly ascribed
n any way to the SES. Fisher exact test for 5 versus 0
tent-related events yielded a p value of 0.054.
These results should not be viewed out of context, nor can
hey be ignored. In this instance, a somewhat-informal
ayesian approach is preferred, considering the likelihood
f excess risk based upon prior data, and then factoring in
he scientific merit of the present publication. Pathobiology
hould be considered, but emotion (and there is a lot of it in
his field) and intuition should be downplayed. One should
nly recall that we once thought that premature ventricular
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July 17, 2007:268–9 Editorial Commentomplexes should be suppressed to eliminate serious ven-
ricular tachycardia and sudden death, to understand that
ntuition is not always correct in our field.
Previous fully peer-reviewed and published data on the
se of SES for de novo SVG lesions is limited to uncon-
rolled registries (11,12). No evidence of excess mortality
eyond expected has been reported.
That said, it is obvious and appropriate to call for more
cientifically rigorous data on this important subset of
atients. Logistical and financial challenges will make this
ifficult. It is quite possible, if not likely, that there is no
xcess risk. In the meantime, however, the cautious physi-
ian might well wish to refrain from using SES in SVG
hose closure might be expected to lead to a large infarc-
ion. Current data, however limited, do not suggest an
xcess stent thrombosis risk when DES are applied to
n-stent restenosis (13).
Finally, there are a number of “big-picture” lessons that
hould be learned from this and similar instances. First, the
.S. Food and Drug Administration should require larger
rials, with broader entry criteria better reflecting the type of
atients who might be treated once devices are approved, for
rials intended for device approval recommendation. Sec-
nd, one must not overreact to the outcome of a study that
t was not specifically designed to address. Such outcomes
hould be considered hypothesis generating. At the same
ime, the paucity of appropriate trial data tends to exagger-
te the importance of whatever data we might have and,
mportantly, physicians must treat their patients on the basis
f the best available data, however flawed it might be.
hird, and this criticism is not at all levied at the authors of
his particular report, it is the serious responsibility of the
nvestigator to educate the media in a balanced fashion
bout their results so that patients attempting to inform
hemselves and become involved in their own medical
ecisions are not misled. This, unfortunately, has not always
een the case recently.
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